SBIR Topic 255: Clinical Translation of Anti-PECAM-1 Monoclonal Antibody as an
SBIR Topic 255: Clinical Translation of Anti-PECAM-1 Monoclonal Antibody as an
SBIR 主题 255：抗 PECAM-1 单克隆抗体作为治疗药物的临床转化
批准号：
8164224
负责人：
ROBERT DEBS
金额：
$19.88万
依托单位：
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
项目状态：
已结题
起止时间：
2010-09-30 至 2011-06-30
关键词：
AntibodiesCD31 AntigensCachexiaCancer PatientClinicalDisseminated Malignant NeoplasmDoseDrug KineticsEnzyme-Linked Immunosorbent AssayFrequenciesGoalsHalf-LifeHumanIntravenousKnowledgeMalignant NeoplasmsMarketingMonoclonal AntibodiesMusNeoplasm MetastasisPatientsPhasePhase I Clinical TrialsRefractoryRiskScheduleSerumSmall Business Innovation Research GrantStagingToxic effectTranslatingTranslationsbasedesignmalignant breast neoplasmmelanomapre-clinicalpreclinical studyresponsetumor
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Most patients who die from cancer succumb to advanced metastatic cancer. These patients, are mostoften treatment-refractory, and comprise the largest untapped market in cancer. We have developed a uniquely effective anti-PECAM-1 monoclonal antibody (mAb)-based therapy. To our knowledge, this mAb is the only treatment that safely and effectively treats advanced tumor metastases, independent of tumor type. Clinical translation of anti-PECAM-1 mAb therapy could revolutionize the treatment of this now-refractory clinical entity. Therefore, we propose to perform the following pre-clinical studies required to translate antiPECAM- 1 mAb-based therapy into phase I clinical trials in cancer patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文